Status:
NOT_YET_RECRUITING
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Advanced Cancer
Pain
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep trac...
Detailed Description
The goal of this study is to develop and refine I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), an electronic health record-integrated mobile health (mHealth) application desig...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Participants (Activities 1a, 2a, 3a):
- Age ≥ 21 years
- Current or previous diagnosis of advanced cancer
- Current or previous experience with cancer pain
- Exclusion Criteria for Participants (Activities 1a, 2a, 3a):
- Inability to understand, speak, or read English
- Any condition that would impede the patient's ability to complete study procedures such as visual impairment or significant cognitive impairment as determined by the participant's treating provider.
Exclusion
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT06117709
Start Date
January 1 2026
End Date
March 30 2026
Last Update
August 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215